Stay updated with breaking news from Clinical Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2...
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The
Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies to prevent and treat...
JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for
JJP Biologics a private biopharmaceutical company developing innovative antibodybased therapies announces a positive decision issued by the European Medicines Agency on the Clinical Trial Application to conduct a phase I clinical study in healthy participants EudraCT 20235086613300 with their potential firstinclass antiCD89 antagonist JJP1212.